# A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

> **NCT00260923** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 641 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** aliskiren

## Key facts

- **NCT ID:** NCT00260923
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260923, "A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00260923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*